Promising COVID-19 treatment trial pulled before it began

NCT ID NCT05137795

Terminated Disease control Sponsor: APR Applied Pharma Research s.a. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study was designed to test whether an inhaled drug called ZYESAMI could help people with severe COVID-19 avoid getting worse and needing a ventilator. It was a Phase 3 trial, meaning it was in the final stage of testing. However, the study was withdrawn before any participants were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZYESAMI (aviptadil acetate)
What this could lead to: If it had worked, this could have pointed toward a new inhaled treatment to prevent severe COVID-19 from getting worse.
What could go wrong: The trial was withdrawn before any participants were enrolled, so no results are available. It is unclear if the treatment would have been safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LUNG INJURY/ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome adult acute respiratory distress syndrome COVID-19 Dyspnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LUNG INJURY/ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ALI ARDS COVID DYSPNEA SARS COV-2

More trials for these conditions

Other studies related to the condition(s) this trial covers.